Gerald Appel, M.D., Ph.D.

Email: gba2@columbia.edu

Dr. Gerald Appel is a Professor of Clinical Medicine at Columbia University, as well as the University’s Director of Clinical Nephrology. Dr. Appel has been an attending physician at Columbia University Medical Center since 1989. He is also the Director of the Glomerular Disease Center at the University. Dr. Appel has served as President of the New York Society of Nephrology and on Medical Advisory Boards of the New York/New Jersey branch of the National Kidney Foundation. In 1998, Dr. Appel was the recipient of the Lester Hoenig Award, the highest award given by the National Kidney Foundation of New York/New Jersey. Dr. Appel was also nominated in New York Magazine’s Best Doctors 2008 edition.

Dr. Appel attended medical school at the Albert Einstein School of Medicine. He completed both his internship and residency at Columbia Presbyterian Medical Center. He accomplished Fellowships in Nephrology at both Columbia Presbyterian and Yale-New Haven Medical Center. He is a member of several committees, including the American Society of Nephrology and the Kidney Council of the American Heart Association.

Dr. Appel’s interests at the Glomerular Disease Center include the study and treatment of Nephrotic Syndrome and FSGS. The center is a collaborative endeavor between the Divisions of Nephrology and Renal Pathology, and is based at the Presbyterian Division of the New York Presbyterian Hospital in New York City. Affiliates of the center join efforts in clinical care, research and education to advance the treatment of Nephrotic Syndrome and FSGS.

Selected Publications
Hogan J, Mohan P, Appel GB. Diagnostic tests and treatment options in glomerular disease: 2014 update. Am J Kidney Dis. 2014; 63(4), 656-666.

Canetta PA, Kiryluk K, Appel GB. Glomerular diseases: Emerging tests and therapies for IgA nephropathy. Clin J Am Soc Nephrol. 2014; 9(3), 617-625.

Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, Appel GB, Radhakrishnan J, Lafayette RA. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol. 2013; 8(12), 2072-2081.

Bomback AS, Canetta PA, Beck LH Jr, Ayalon R, Radhakrishnan J, Appel GB. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol. 2012; 36(1), 58-67.

Papeta N, Kiryluk K, Patel A, Sterken R, Kacak N, Snyder HJ, Imus PH, Mhatre AN, Lawani AK, Julian BA, Wyatt RJ, Novak J, Wyatt CM, Ross MJ, Winston JA, Klotman ME, Cohen DJ, Appel GB, D’Agati VD, Klotman PE, Gharavi AG. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol. 2011; 22(11), 1991-1996.

Bomback AS, Tumlin JA, Baranski J, Bourdeau JE, Besarab A, Appel AS, Radhakrishnan J, Appel GB. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther. 2011; 5, 147-153.

Liakopoulos V, Huerta A, Cohen S, Pollak MR, Sirota RA, Superdock K, Appel GB. Familial collapsing focal segmental glomerulosclerosis. Clin Nephrol. 2011; 75(4): 362-368.

Schachter ME, Monahan M, Radhakrishnan J, Crew J, Pollak M, Ratner L, Valeri AM, Stokes MB, Appel GB (2010). Recurrent focal segmental glomerulosclerosis in the renal allograft: Single center experience in the era of modern immunosuppression. Clin Nephrol, 74(3), 173-181.

Genovese G, Tonna SJ, Knob AU, Appel GB, Katz A, Bernhardy AJ, Needham AW, Lazarus R, Pollak MR (2010). A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int, 78(7), 698-704.

College of Physicians and Surgeons, Columbia University